Oxana Denisova
PhD
oxana.denisova@utu.fi Työhuone: 4120 ORCID-tunniste: https://orcid.org/0000-0002-7041-3842 |
Cancer cell signaling; kinases; protein phosphatase 2A; anticancer and antiviral agents, virus-host interaction
Education and degrees completed
26th August 2014 Ph.D. in Medicine (Molecular Virology), Faculty of Medicine, University of Helsinki, Finland. Topic: "Influenza virus-host interactions and their modulation by small molecules".
29th June 2007 M.Sc. in Biology (Molecular Biology) (Hons.), Lobachevsky State University of Nizhny Novgorod, Russia. Topic: "Development of genomic approach for high-throughput analysis of CCWGG methylation".
09.2005 – 05.2007 training at the Molecular Biology Education Centre, Institute of Protein Research, Pushchino, Russia, included in MSc degree. Topic: "Cloning and purification of site-specific endonuclease EcoRIIC".
Current position
01.2015 – present Postdoctoral researcher at Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Previous work experience
06.2011 – 05.2014 PhD researcher, Institute for Molecular Medicine Finland, Helsinki, Finland.
10.2008 – 10.2011 Researcher, Institute of Theoretical and Experimental Biophysics, Pushchino, Russia.
09.2007 – 10.2008 Researcher, Institute of Protein Research, Pushchino, Russia.
Career breaks
05.2016 – 08.2017 Maternity leave.
- PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells (2023)
- Molecular Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)) - Protein phosphatase PP2A-based triple-strike therapy for medulloblastoma (2023)
- Molecular Oncology
(Muu (O2)) - Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells (2022)
- Scientific Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)) - Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma (2020)
- Brain Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)) - Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide (2019)
- International Journal of Cancer
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)) - PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells (2016)
- Cancer Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))